Abstract: Angiotensin type-1 receptor blockers (ARBs) are being one of the first-line treatments for hypertension. Despite the availability of various types of ARBs, there are no comparative studies of their effects in North Indian patients. In this open-label, prospective, randomized study, we compared the antihypertensive effects of olmesartan (20 mg/day) versus telmisartan (40 mg/day) in newly diagnosed patients of stage I hypertension as defined under JNC-VII guidelines. 60 patients were randomized into 2 groups. The odd numbers was allotted to olmesartan (group A) & even numbers to telmisartan (group B). Group A was allotted olmesartan 20 mg/day and group B was given telmisartan 40 mg/day for 12 weeks. Efficacy and safety was assessed by the changes in the blood pressure in terms of adverse event rates and control of blood pressure, including abnormal clinical laboratory variables related to kidney function and serum electrolyte levels. The follow up was done at 2, 4, 8 and 12 weeks. We analyzed the blood pressure lowering effects of each drug by blood pressure monitoring at 0, 2, 4, 8, 12 weeks and metabolic parameters were assessed. Olmesartan lowered mean systolic and diastolic blood pressure more significantly than telmisartan. Our results indicate that olmesartan has more potent arterial blood pressure lowering effect than telmisartan. None of the patient complained about any adverse effect with the use of either olmesartan (20mg per day) or telmisartan (40mg/day).
INTRODUCTION:
Hypertension is a multifactorial disease and is the most common, readily identifiable and reversible risk factor for myocardial infarction, stroke, kidney disease and blindness. A sustained increase in blood pressure > 140/90mm Hg and is associated with marked morbidity and mortality [1] .
Renin angiotensin system (RAS) plays an important role in pathophysiology of cardiovascular disease. Angiotensin II receptor blockers (ARBs) are being used as one of the agents for the treatment of hypertension and are known to be effective in the prevention of cardiovascular end-organ damage because of its anti-inflammatory and anti-oxidant effects [2, 3] . They are also more beneficial in lowering the risk of type 2 diabetes mellitus in comparison with other antihypertensives. ARBs prevent the hypertensive effects of angiotensin II by selective blockade of the angiotensin II type 1 (AT1) receptor [4] .
Although many researches have been done so far to compare the antihypertensive efficacy of ARBs, but such comparative studies have mainly been conducted against Losartan only [5] . It was reported in few studies, that olmesartan exerts strong antihypertensive effect by its higher selectively and very strong binding with AT1 receptor [6] . While Telmisartan has more sustained reduction in blood pressure by a longer residence time on AT1 receptor [7, 8] . Therefore, in the present study, we were interested in comparing the efficacy and safety of olmesartan versus telmisartan in patients of stage 1(JNCVII) hypertension.
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AIM AND OBJECTIVES
To comparatively evaluate the antihypertensive efficacy and safety of OLMESARTAN 20 mg versus TELMISARTAN 40 mg in stage 1 hypertensive patients (JNC VII)
MATERIAL AND METHODS
A prospective one year randomized open label interventional clinical study was conducted amongst the patients diagnosed with hypertension stage-1(JNCVII) attending to the medicine OPD of RMCH, Bareilly after ethical clearance by IEC(institutional ethical committee) and written informed consent of the subjects.
Study was conducted for 3 months and all the patients during 3 months of study period of age group 30 to 80 years of both genders attending medicine OPD diagnosed with hypertension stage -1 (JNCVII), were enrolled after doing relevant investigations.
DATA ANALYSIS
Statistical analysis was done by using specific software SPSS version 20. The results are displayed with the help of tables. A total of 60 patients of age 30-80 years of both genders of all socio-economic status were enrolled for the study and then randomized into olmesartan and telmisartan group. The odd numbers were allotted to olmesartan & even numbers to telmisartan.
Inclusion Criteria
All patients of both the genders, aged 30 to 80 years of stage 1 hypertension was included in the study Exclusion Criteria- Patient of age group less than 30 and more than 80 years.  The subjects with presence of history of any acute or chronic disease that would affect the study variables were excluded.  Pregnant and lactating females.  History of Significant renal disease or liver and cardiovascular disease.  Known hypersensitivity to angiotensin receptor.
Baseline Investigations Done In all patients -
Haemogram -Hb, TLC, DLC, ESR, GBP, Blood sugar fasting/Blood Sugar PP or RBS, Serum Creatinine, Serum k+ levels, Blood Urea ,SGPT, Fasting lipid profile, Urine Routine & Microscopy Exam, Chest X ray PA view, ECG.
 Done In Selected Patients
Fundoscopy for retinopathy, Fasting T3, T4, TSH in thyroid disorder patients Table 1 shows the demographic characteristic of the patients in which differences were found to be statistically non-significant in both the groups. Hence both Olmesartan and Telmisartan treated groups were comparable with respect to age, gender, locality, education and socioeconomic status. In this study, olmesartan treated patients (Gp A) showed statistically significant reduction both in SBP and DBP as compared to Telmisartan (Gp B) in all the follow-ups (SBP at 2wk, P= 0.0345, 1 month, P= 0.0175, 2 month, p> 0.0029 and 3 month, P= 0.0296 and 3 month P = 0.0472), Our findings are consistent with the study by Nakayama S et al.; [9] . who observed that Olmesartan lowered systolic, diastolic and mean blood pressure by 3.3, 2.7 and 3.1 mm Hg more than did Telmisartan (P=0.0305, 0.0087 and 0.0058 for SBP, DBP and mean BP respectively). Moreover, their data also reported that olmesartan at 20mg/day Lowered BP more than telmisartan at 40 mg/day. Further they observed that olmesartan therapy lowered mean systolic and diastolic BP to below 130/80mm Hg which JNC7 [10] and ESH/ESC [11] both recommended.
RESULTS:
Smith et al.; [12] observed that olmesartan is significantly more effective than Losartan or valsartan as antihypertensive, similarly Mirza et al.; [13] reported that, olmesartan regarding BP lowering agent may have strong vaso-depressor effect and has dual inverse agonism i.e. strong inverse agonistic action towards inositol triphosphate (IP) production and extracellular signal regulated kinase action independent of Ang II stimulation, which might be responsible of greater lowering of blood pressure.
Few other researchers [14, 15] also supported our findings. Another explanation for greater BP lowering effect of olmesartan as compared to Telmisartan was explained in the study of Le et al.; [16] , which in addition reported that although both ARBs were competitive antagonist at but olmesartan had higher affinity, greater degree of unsorrmountability and slower dissociation from AT1 receptor than telmisartan. A number of studies [17] [18] [19] also depicted that olmesartan showed a greater binding with AT1 receptor and a better antihypertensive than other ARBs.
However, many studies do not support our findings. Pathapati et al.; [20] found no statistically significant difference between the two groups with respect to reduction in SBP and DBP both. In another study by Luis DA et al.; [21] both drugs had similar blood pressure lowering effect in hypertensive obese patients.
Another contradiction was observed by Arao et al.; [20] . In their cross-over study, no significant difference in antihypertensive effect between olmesartan and Telmisartan were found (SBP. P-0.543, DBP, P= 0.308). Our study contradict the study of Sasaki et al.; [23] who documented telmisartan to be more effective blood pressure lowering agent as compared to olmesartan.
In this study we also compared the effects of olmesartan and telmisartan on biochemicals parameters. Despite various types of ARBs are available, there are few studies which compared the effect on biochemical profile. We found no statistically significant alterations within the two groups as well as when mean of both groups were compared. Nakayana et al.; [9] also observed no significant alteration in biochemical parameters which supported our observations. In 2 months study by Kumar et [25] in their 12 week study observed no statistically significant difference in FBS (mg/dl) S. urea (mg/dl) and S. Creatinine (mg/dl) values when mean of the two groups were compared. This is in accordance with our findings. But there significant decrease in serum urea and s. creatinine from baseline to end point within the groups of olmesartan and Telmisartan inhibitors which is contradictory with our study.
Arao et al.; [22] reported significant reduction in FBS with olmesartan (P=0.006) than telmisartan and they suggested olmesartan to be superior to telmisartan in term of improving glucose metabolism, insulin resistance and lipid metabolism.
Ramachendran et al.; [26] reported that although olmesartan is more potent as Blood pressure lowering agent than Telmisartan but not observed with metabolic parameters.
CONCLUSION:
Olmesartan showed a better reduction in blood pressure with similar effects in biochemical parameters as telmisartan.
LIMITATIONS:
As this study was of 3 months duration, so long term results cannot be depicted. Therefore longer duration of study may be required to observe the effect of olmesartan and telmisartan on blood pressure and metabolic parameters.
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